1.955  -0.035 (-1.76%)		03-16 15:59
Open: 1.97 High: 2.03 Volume: 258,479		Pre. Close: 1.99 Low: 1.95 Market Cap: 94(M)

Short term
Mid term
Targets	6-month :	2.52	1-year :	2.9
Resists	First :	2.16	Second :	2.49
Pivot price	1.93
Supports	First :	1.63	Second :	1.36
MAs	MA(5) :	1.8	MA(20) :	1.99
	MA(100) :	2.38	MA(250) :	2.34
MACD	MACD :	-0.2	Signal :	-0.1
%K %D	K(14,3) :	4.2	D(3) :	6.3
RSI	RSI(14): 35.3
52-week	High :	4.98	Low :	1.14

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ SAVA ] has closed above bottom band by 11.1%. Bollinger Bands are 12.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	1.75 - 1.76	1.76 - 1.77
Low:	1.61 - 1.63	1.63 - 1.64
Close:	1.65 - 1.68	1.68 - 1.69

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

Sun, 19 Apr 2026
SAVA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Cassava Sciences, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire

Thu, 02 Apr 2026
Cassava Sciences (NASDAQ:SAVA) Stock Price Up 1.8% - Here's What Happened - MarketBeat

Tue, 10 Mar 2026
Cassava Sciences Rebrands as Filana Therapeutics, Updates Ticker - TipRanks

Tue, 10 Mar 2026
Cassava Sciences, Inc. will Change its Ticker to FLNA from SAVA - marketscreener.com

Tue, 10 Mar 2026
Filana Therapeutics (NASDAQ: FLNA) adopts new name and FLNA ticker - Stock Titan

Tue, 10 Mar 2026
Cassava Sciences Announces Name Change to Filana Therapeutics, Inc. - Yahoo Finance

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	48 (M)
Shares Float	43 (M)
Held by Insiders	12.7 (%)
Held by Institutions	28.9 (%)
Shares Short	7,120 (K)
Shares Short P.Month	7,170 (K)

EPS	-2.23
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	1.69
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-24.8 %
Return on Equity (ttm)	-85.5 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	-0.9
Sales Per Share	0
EBITDA (p.s.)	-1.44
Qtrly Earnings Growth	0 %
Operating Cash Flow	-84 (M)
Levered Free Cash Flow	19 (M)

PE Ratio	-0.76
PEG Ratio	0
Price to Book value	0.99
Price to Sales	0
Price to Cash Flow	-0.97

Dividend	5.25
Forward Dividend	0
Dividend Yield	313%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.